Cargando…
Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling
Pulmonary arterial hypertension is a disease of proliferative vascular occlusion that is strongly linked to mutations in BMPR2—the gene encoding the BMPR-II (BMP [bone morphogenetic protein] type II receptor). The endothelial-selective BMPR-II ligand, BMP9, reverses disease in animal models of pulmo...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571847/ https://www.ncbi.nlm.nih.gov/pubmed/32998516 http://dx.doi.org/10.1161/ATVBAHA.119.313357 |
_version_ | 1783597231813689344 |
---|---|
author | Theilmann, Anne L. Hawke, Lindsey G. Hilton, L. Rhiannon Whitford, Mara K.M. Cole, Devon V. Mackeil, Jodi L. Dunham-Snary, Kimberly J. Mewburn, Jeffrey James, Paula D. Maurice, Donald H. Archer, Stephen L. Ormiston, Mark L. |
author_facet | Theilmann, Anne L. Hawke, Lindsey G. Hilton, L. Rhiannon Whitford, Mara K.M. Cole, Devon V. Mackeil, Jodi L. Dunham-Snary, Kimberly J. Mewburn, Jeffrey James, Paula D. Maurice, Donald H. Archer, Stephen L. Ormiston, Mark L. |
author_sort | Theilmann, Anne L. |
collection | PubMed |
description | Pulmonary arterial hypertension is a disease of proliferative vascular occlusion that is strongly linked to mutations in BMPR2—the gene encoding the BMPR-II (BMP [bone morphogenetic protein] type II receptor). The endothelial-selective BMPR-II ligand, BMP9, reverses disease in animal models of pulmonary arterial hypertension and suppresses the proliferation of healthy endothelial cells. However, the impact of BMPR2 loss on the antiproliferative actions of BMP9 has yet to be assessed. APPROACH AND RESULTS: BMP9 suppressed proliferation in blood outgrowth endothelial cells from healthy control subjects but increased proliferation in blood outgrowth endothelial cells from pulmonary arterial hypertension patients with BMPR2 mutations. This shift from growth suppression to enhanced proliferation was recapitulated in control human pulmonary artery endothelial cells following siRNA-mediated BMPR2 silencing, as well as in mouse pulmonary endothelial cells isolated from endothelial-conditional Bmpr2 knockout mice (Bmpr2(EC)(−/−)). BMP9-induced proliferation was not attributable to altered metabolic activity or elevated TGFβ (transforming growth factor beta) signaling but was linked to the prolonged induction of the canonical BMP target ID1 in the context of BMPR2 loss. In vivo, daily BMP9 administration to neonatal mice impaired both retinal and lung vascular patterning in control mice (Bmpr2(EC+/+)) but had no measurable effect on mice bearing a heterozygous endothelial Bmpr2 deletion (Bmpr2(EC+/−)) and caused excessive angiogenesis in both vascular beds for Bmpr2(EC)(−/−) mice. CONCLUSIONS: BMPR2 loss reverses the endothelial response to BMP9, causing enhanced proliferation. This finding has potential implications for the proposed translation of BMP9 as a treatment for pulmonary arterial hypertension and suggests the need for focused patient selection in clinical trials. GRAPHIC ABSTRACT: A graphic abstract is available for this article. |
format | Online Article Text |
id | pubmed-7571847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-75718472020-10-29 Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling Theilmann, Anne L. Hawke, Lindsey G. Hilton, L. Rhiannon Whitford, Mara K.M. Cole, Devon V. Mackeil, Jodi L. Dunham-Snary, Kimberly J. Mewburn, Jeffrey James, Paula D. Maurice, Donald H. Archer, Stephen L. Ormiston, Mark L. Arterioscler Thromb Vasc Biol Basic Sciences Pulmonary arterial hypertension is a disease of proliferative vascular occlusion that is strongly linked to mutations in BMPR2—the gene encoding the BMPR-II (BMP [bone morphogenetic protein] type II receptor). The endothelial-selective BMPR-II ligand, BMP9, reverses disease in animal models of pulmonary arterial hypertension and suppresses the proliferation of healthy endothelial cells. However, the impact of BMPR2 loss on the antiproliferative actions of BMP9 has yet to be assessed. APPROACH AND RESULTS: BMP9 suppressed proliferation in blood outgrowth endothelial cells from healthy control subjects but increased proliferation in blood outgrowth endothelial cells from pulmonary arterial hypertension patients with BMPR2 mutations. This shift from growth suppression to enhanced proliferation was recapitulated in control human pulmonary artery endothelial cells following siRNA-mediated BMPR2 silencing, as well as in mouse pulmonary endothelial cells isolated from endothelial-conditional Bmpr2 knockout mice (Bmpr2(EC)(−/−)). BMP9-induced proliferation was not attributable to altered metabolic activity or elevated TGFβ (transforming growth factor beta) signaling but was linked to the prolonged induction of the canonical BMP target ID1 in the context of BMPR2 loss. In vivo, daily BMP9 administration to neonatal mice impaired both retinal and lung vascular patterning in control mice (Bmpr2(EC+/+)) but had no measurable effect on mice bearing a heterozygous endothelial Bmpr2 deletion (Bmpr2(EC+/−)) and caused excessive angiogenesis in both vascular beds for Bmpr2(EC)(−/−) mice. CONCLUSIONS: BMPR2 loss reverses the endothelial response to BMP9, causing enhanced proliferation. This finding has potential implications for the proposed translation of BMP9 as a treatment for pulmonary arterial hypertension and suggests the need for focused patient selection in clinical trials. GRAPHIC ABSTRACT: A graphic abstract is available for this article. Lippincott Williams & Wilkins 2020-10-01 2020-11 /pmc/articles/PMC7571847/ /pubmed/32998516 http://dx.doi.org/10.1161/ATVBAHA.119.313357 Text en © 2020 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. |
spellingShingle | Basic Sciences Theilmann, Anne L. Hawke, Lindsey G. Hilton, L. Rhiannon Whitford, Mara K.M. Cole, Devon V. Mackeil, Jodi L. Dunham-Snary, Kimberly J. Mewburn, Jeffrey James, Paula D. Maurice, Donald H. Archer, Stephen L. Ormiston, Mark L. Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling |
title | Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling |
title_full | Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling |
title_fullStr | Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling |
title_full_unstemmed | Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling |
title_short | Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling |
title_sort | endothelial bmpr2 loss drives a proliferative response to bmp (bone morphogenetic protein) 9 via prolonged canonical signaling |
topic | Basic Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571847/ https://www.ncbi.nlm.nih.gov/pubmed/32998516 http://dx.doi.org/10.1161/ATVBAHA.119.313357 |
work_keys_str_mv | AT theilmannannel endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT hawkelindseyg endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT hiltonlrhiannon endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT whitfordmarakm endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT coledevonv endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT mackeiljodil endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT dunhamsnarykimberlyj endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT mewburnjeffrey endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT jamespaulad endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT mauricedonaldh endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT archerstephenl endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling AT ormistonmarkl endothelialbmpr2lossdrivesaproliferativeresponsetobmpbonemorphogeneticprotein9viaprolongedcanonicalsignaling |